Number needed to treat and cost per remitter for biologic treatments of Crohn’s disease in Japan

AbstractAims: Adalimumab, infliximab, and ustekinumab have been approved for patients with moderate-to-severe Crohn’s disease in Japan. This study compared the relative efficacy and cost effectiven...